Cara Therapeutics, Inc. (CARA)
Market Cap | 15.90M |
Revenue (ttm) | 11.00M |
Net Income (ttm) | -111.08M |
Shares Out | 54.85M |
EPS (ttm) | -2.04 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 137,393 |
Open | 0.290 |
Previous Close | 0.287 |
Day's Range | 0.283 - 0.299 |
52-Week Range | 0.240 - 1.680 |
Beta | 0.70 |
Analysts | Hold |
Price Target | 1.00 (+244.95%) |
Earnings Date | Nov 11, 2024 |
About CARA
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruish... [Read more]
Financial Performance
In 2023, Cara Therapeutics's revenue was $20.97 million, a decrease of -49.92% compared to the previous year's $41.87 million. Losses were -$118.51 million, 38.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CARA stock is "Hold." The 12-month stock price forecast is $1.0, which is an increase of 244.95% from the latest price.
News
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.
Cara Therapeutics discontinues study on a neurological condition as drug fails
Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical...
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June ...
Cara Therapeutics Reports First Quarter 2024 Financial Results
Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 Topline efficacy and safety results from KOURAGE 1 Part ...
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Ch...
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patie...
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patie...
Cara Therapeutics, Inc. (CARA) Q4 2023 Earnings Call Transcript
Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2023 Earnings Call Transcript March 4, 2024 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - ...
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)–
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:...
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need –
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruri...
Cara Therapeutics, Inc. (Cara) Q3 2023 Earnings Call Transcript
Cara Therapeutics, Inc. (Cara) Q3 2023 Earnings Call Transcript November 13, 2023 4:30 PM ET Company Participants Matt Murphy - Manager of IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - Ch...
Cara Therapeutics Reports Third Quarter 2023 Financial Results
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 –
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
Transaction supports progression of late-stage oral difelikefalin clinical programs Non-dilutive capital expected to extend cash runway into 2025 STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Car...
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...
Cara Therapeutics, Inc. (CARA) Q2 2023 Earnings Call Transcript
Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Matthew Murphy - Manager, IR Christopher Posner - President, CEO & Director Ryan ...
Cara Therapeutics Reports Second Quarter 2023 Financial Results
– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company's share of profit of KORSUVA ® (difelikefalin) injection –
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
Cara Therapeutics Faces Uncertainty Despite Potential Reimbursement Extension For Korsuva
Cara Therapeutics' Korsuva injection, approved for treating pruritus in adults with chronic kidney disease, may have its reimbursement period extended to 2027 by the US Medicare and Medicaid Services,...
Cara Therapeutics to Present at the Jefferies Healthcare Conference
STAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...